United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.
For more coronavirus news, visit our dedicated page.
The US government is “cautiously optimistic” that one or two vaccines, likely from Pfizer Inc or Moderna Inc, will be available by the end of the year and can begin to be distributed to Americans, officials said during a news conference.
Azar said he expects all seniors, healthcare workers, and first responders will be able to receive a vaccine as soon as January, with the rest of the American public able to get a vaccine by April.
Companies participating in the US government’s effort to develop a vaccine for COVID-19, dubbed Operation Warp Speed, have begun developing manufacturing capabilities even before any vaccinations have been authorized by regulators.
In an open letter published last week, Pfizer said it is unlikely to have enough data to submit for a US regulatory authorization until late November, after the US presidential election.
The coronavirus outbreak has been worsening in recent weeks as cold weather pushes Americans indoors, raising the chance of contracting the virus. Some 38 US states and two territories have reported rising case counts.
More than 8 million Americans have been infected with the novel coronavirus and more than 200,000 have died.
Coronavirus: Russia’s Putin pitches COVID-19 vaccine to tycoons as $100 bln chancePresident Vladimir Putin pitched the potential of Russia’s unproven Covid-19 vaccine to a group of top business leaders Wednesday as the country is ... Coronavirus
Coronavirus: Next up in search for COVID-19 vaccine is testing shots in childrenThe global hunt for a COVID-19 vaccine for kids is only just beginning — a lagging start that has some US pediatricians worried they may not know if ... Coronavirus
Coronavirus: Oxford’s Brazil COVID-19 vaccine trial to continue after volunteer diesThe University of Oxford's Brazilian trial of its vaccine candidate will continue after the death of a volunteer, the university said on Wednesday, ... Coronavirus